PYRIMIDINE COMPOUNDS

摘要

This invention features pyrimidine compounds of formula (I): R1 is formula (II), aryl, or heteroaryl; each of R2 and R4, independently, is R, halogen, nitro, cyano, isothionitro, SR, or OR; or R2 and R4, taken together, is carbonyl; R3 is R, alkenyl, alkynyl, OR, OC(O)R, S02R, S(O)R, S(02)NRR, SR, NRR, NRCOR, NRC(O)OR, NRC(O)NRR, NRS02R, COR, C(O)OR, or C(O)NRR; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is O, S, S(O), S(02), or NR; Y is a covalent bond, CH2, C(O), C=N-R, C=N-OR, C=N-SRc, O, S, S(O), S(02), or NR; Z is N or CH; one of U and V is N, and the other is CR; and W is O, S, S(O), S(02), NR, or NC(O)R; in which each of R and R, independently, is H, alkyl, aryl, heteroaryl; and each of R and R, independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl. The compounds are useful for treating IL-12 overproduction related diseases (e.g., rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus).